Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H18N4O |
| Molecular Weight | 270.3296 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(N[C@@H]1CN2CCC1CC2)C3=NNC4=C3C=CC=C4
InChI
InChIKey=TXCYUSKWBHUVEP-CYBMUJFWSA-N
InChI=1S/C15H18N4O/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18)/t13-/m1/s1
| Molecular Formula | C15H18N4O |
| Molecular Weight | 270.3296 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Facinicline (MEM-63908 or R-4996) is a selective nicotinic alpha-7 receptor (α7nAChR) partial agonist. It also has properties of a serotonin 3 receptor antagonist. It has hydrochloride form: RG3487 (formerly MEM3454). Facinicline enhances DA efflux by nAChR stimulation, whereas ACh efflux is primarily mediated via 5-HT3 receptor antagonism. It improves cognition and sensorimotor gating in rodents. It has been tested in Alzheimer's disease and cognitive symptoms of schizophrenia.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. | 2014-06 |
|
| The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. | 2014-05 |
|
| RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. | 2011-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:25:01 GMT 2025
by
admin
on
Mon Mar 31 20:25:01 GMT 2025
|
| Record UNII |
6A6FX0J03K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C166923
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
677306-35-3
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
DTXSID90218011
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
DB05586
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
9970357
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
6A6FX0J03K
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
300000034250
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY | |||
|
9456
Created by
admin on Mon Mar 31 20:25:01 GMT 2025 , Edited by admin on Mon Mar 31 20:25:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |